


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:42Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406146" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406146</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Neurol</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Neurology</journal-title></journal-title-group><issn pub-type="ppub">2168-6149</issn><issn pub-type="epub">2168-6157</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406146</article-id><article-id pub-id-type="pmcid-ver">PMC12406146.1</article-id><article-id pub-id-type="pmcaid">12406146</article-id><article-id pub-id-type="pmcaiid">12406146</article-id><article-id pub-id-type="pmid">40892424</article-id><article-id pub-id-type="doi">10.1001/jamaneurol.2025.3151</article-id><article-id pub-id-type="publisher-id">noi250058</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage</article-title><subtitle>The MIND Randomized Clinical Trial</subtitle><alt-title alt-title-type="headline">Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage</alt-title><alt-title alt-title-type="running-head">Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Arthur</surname><given-names initials="AS">Adam S.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="noi250058aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jahromi</surname><given-names initials="BS">Babak S.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saphier</surname><given-names initials="PS">Paul S.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="noi250058aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nickele</surname><given-names initials="CM">Christopher M.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ryan</surname><given-names initials="RW">Robert W.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vajkoczy</surname><given-names initials="P">Peter</given-names></name><degrees>MD</degrees><xref rid="noi250058aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schirmer</surname><given-names initials="CM">Clemens M.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kellner</surname><given-names initials="CP">Christopher P.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Matouk</surname><given-names initials="CC">Charles C.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Arias</surname><given-names initials="EJ">Eric J.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ullman</surname><given-names initials="JS">Jamie S.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Levitt</surname><given-names initials="MR">Michael R.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hage</surname><given-names initials="ZA">Ziad A.</given-names></name><degrees>MD</degrees><xref rid="noi250058aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fiorella</surname><given-names initials="DJ">David J.</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref rid="noi250058aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><on-behalf-of>for the MIND Study Investigators and Collaborators</on-behalf-of></contrib-group><aff id="noi250058aff1"><label>1</label>Department of Neurosurgery, Semmes-Murphey Clinic and University of Tennessee Health Sciences Center, Memphis</aff><aff id="noi250058aff2"><label>2</label>Department of Neurological Surgery, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois</aff><aff id="noi250058aff3"><label>3</label>Coaxial Neurosurgical Specialists, Morristown, New Jersey</aff><aff id="noi250058aff4"><label>4</label>Overlook Medical Center, Summit, New Jersey</aff><aff id="noi250058aff5"><label>5</label>Virginia Mason Medical Center, Seattle, Washington</aff><aff id="noi250058aff6"><label>6</label>Charit&#233; Universit&#228;tsmedizin Berlin, Berlin, Germany</aff><aff id="noi250058aff7"><label>7</label>Department of Neurosurgery, Geisinger Commonwealth School of Medicine, Danville, Pennsylvania</aff><aff id="noi250058aff8"><label>8</label>Mount Sinai Hospital, New York, New York</aff><aff id="noi250058aff9"><label>9</label>Department of Neurosurgery, Yale University, New Haven, Connecticut</aff><aff id="noi250058aff10"><label>10</label>CarePoint Neurosurgery, HCA HealthONE Swedish, Englewood, Colorado</aff><aff id="noi250058aff11"><label>11</label>Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York</aff><aff id="noi250058aff12"><label>12</label>Departments of Neurological Surgery, Radiology, Neurology, and Mechanical Engineering and Stroke &amp; Applied NeuroScience Center, University of Washington, Seattle</aff><aff id="noi250058aff13"><label>13</label>Novant Health Presbyterian Medical Center, Charlotte, North Carolina</aff><aff id="noi250058aff14"><label>14</label>Stony Brook University Hospital, Stony Brook, New York</aff><author-notes><title>Article Information</title><p content-type="byline-footnote" specific-use="print"><bold>Group Information:</bold> The MIND Study Investigators and Collaborators are listed in Supplement 3.</p><p><bold>Accepted for Publication:</bold> June 12, 2025.</p><p content-type="published-online"><bold>Published Online:</bold> September 2, 2025. doi:<uri content-type="doi">10.1001/jamaneurol.2025.3151</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-nc-nd-license-permissions" ext-link-type="uri">CC-BY-NC-ND License</ext-link>, which does not permit alteration or commercial use, including those for text and data mining, AI training, and similar technologies. &#169; 2025 Arthur AS et al. <italic toggle="yes">JAMA Neurology</italic>.</p><corresp id="noi250058cor1"><bold>Corresponding Author:</bold> Adam S. Arthur, MD, MPH, Department of Neurosurgery, Semmes-Murphey Clinic and University of Tennessee Health Sciences Center, 6325 Humphreys Blvd, Memphis, TN 38120 (<email xlink:href="aarthur@semmes-murphey.com">aarthur@semmes-murphey.com</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Arthur and Fiorella had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Arthur and Fiorella contributed equally to this work.</p><p><italic toggle="yes">Concept and design:</italic> Arthur, Jahromi, Vajkoczy, Fiorella.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Schirmer, Fiorella.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> All authors.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Arthur, Jahromi, Levitt, Hage.</p><p><italic toggle="yes">Supervision:</italic> Arthur, Jahromi, Ryan, Vajkoczy, Arias, Levitt, Hage, Fiorella.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Arthur reported personal fees from Penumbra during the conduct of the study and holding equity in inTRAvent outside the submitted work. Dr Jahromi reported grants from Penumbra during the conduct of the study. Dr Nickele reported stock ownership in Neuroventx outside the submitted work. Dr Schirmer reported grants from Penumbra during the conduct of the study; grants from Balt, Cerenovus, Medtronic, Microvention, MIVI Neuroscience, Route 92 Medical, Stryker, and the US National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS); personal fees from Balt, Medtronic, Microvention, Stryker, and Werfen; and ownership of NTI/REIST (venture capital funds focused on medical technology) outside the submitted work. Dr Kellner reported grants from Integra and Penumbra and serving as founder of Borealis outside the submitted work. Dr Matouk reported personal fees from Penumbra, Silk Road, and Terumo MicroVention; holding equity interest in Jiva Medical; and grants from CereVasc for serving as national principal investigator of the STRIDE trial outside the submitted work. Dr Arias reported personal fees from Penumbra outside the submitted work. Dr Ullman reported patient enrollment payments sent to the Feinstein Institute of Medical Research of Northwell Health from Penumbra during the conduct of the study. Dr Levitt reported grants from Medtronic and Stryker; holding equity interest in Apertur, Fluid Biomed, Hyperion Surgical, Proprio, Stroke Diagnostics, and Synchron; consultant fees from Aeaean Advisers, Arsenal Medical, Genomadix, and Stereotaxis; and serving as an advisor for METIS Innovative, on the editorial board for the <italic toggle="yes">Journal of NeuroInterventional Surgery</italic>, and on a data safety monitoring board for Arsenal Medical outside the submitted work. Dr Hage reported consulting or speaker fees from Balt, Medtronic, and Stryker outside the submitted work. Dr Fiorella reported grants from SUNY Stony Brook for serving in a principal investigator role in study during the conduct of the study. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported by Penumbra, Inc.</p><p><bold>Role of the Funding/Sponsors:</bold> Penumbra contributed to the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Group Information:</bold> The MIND Study Investigators and Collaborators are listed in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p><p><bold>Meeting Presentations:</bold> A portion of this analysis was presented at the Congress of Neurological Surgeons; September 28 to October 2, 2024; Houston, Texas; and at the International Stroke Conference; February 5-7, 2025; Los Angeles, California.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 4</xref>.</p><p><bold>Additional Contributions:</bold> We thank data safety monitoring board and clinical events committee members, the Imaging Core Laboratory, all site teams, and Berry Consultants for their contribution to the study. We also thank Penumbra employees Joel Estis, MS, for statistical assistance (ie, secondary and exploratory analysis) and Joanna Kur, PhD, for writing assistance.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-09-02T10:00"><day>2</day><month>9</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">496127</issue-id><elocation-id>e253151</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 Arthur AS et al. <italic toggle="yes">JAMA Neurology</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY-NC-ND License, which does not permit alteration or commercial use, including those for text and data mining, AI training, and similar technologies.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jamaneurol-e253151.pdf"/><self-uri content-type="pdf-version" xlink:href="jamaneurol-e253151.pdf">jamaneurol-e253151.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archneur/fullarticle/10.1001/jamaneurol.2025.3151"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-noi250058-1"><title>Question</title><p>Can minimally invasive surgery with the Artemis Neuro Evacuation Device improve outcomes in patients with spontaneous supratentorial intracerebral hemorrhage?</p></sec><sec id="ab-noi250058-2"><title>Findings</title><p>The MIND randomized clinical trial stopped early, given the positive results of a contemporaneous trial and the outcome of a subsequent feasibility analysis; however, the available data for 236 participants suggest that minimally invasive surgery (within 72 hours of symptom onset) did not improve 180-day disability or reduce 30-day mortality in patients with spontaneous supratentorial intracerebral hemorrhage compared to guideline-based medical management. Minimally invasive surgery significantly improved 30-day disability and reduced the occurrence of 180-day serious adverse events.</p></sec><sec id="ab-noi250058-3"><title>Meaning</title><p>While MIND did not demonstrate a benefit of minimally invasive surgery over medical management with respect to reducing 180-day disability or 30-day mortality, the Artemis system achieved efficient, safe, and substantial hemorrhage reduction in both deep and lobar bleeds.</p></sec></abstract><abstract><sec id="ab-noi250058-4"><title>Importance</title><p>It remains uncertain whether surgical evacuation improves functional outcomes in patients with supratentorial intracerebral hemorrhage (ICH).</p></sec><sec id="ab-noi250058-5"><title>Objective</title><p>To compare the safety and efficacy of minimally invasive surgery with the Artemis Neuro Evacuation Device to guideline-based medical management alone for spontaneous supratentorial ICH.</p></sec><sec id="ab-noi250058-6"><title>Design, Setting, and Participants</title><p>The MIND open-label, multicenter randomized clinical trial randomized patients with spontaneous supratentorial ICH in a 2:1 ratio to either minimally invasive surgery or medical management alone. Participants were enrolled at 32 participating global sites between February 6, 2018, and August 28, 2023. This article reports on the primary trial outcome. Of 4066 eligible adult patients (aged 18-80 years) with moderate- to large-volume supratentorial ICH (20-80 mL), baseline National Institutes of Health Stroke Scale score of 6 or higher, and Glasgow Coma Scale score between 5 and 15, 154 were randomized to minimally invasive surgery and 82 to medical management. Data were analyzed from February to September 2024.</p></sec><sec id="ab-noi250058-7"><title>Intervention</title><p>Minimally invasive surgery (within 72 hours of symptom onset) plus medical management or medical management alone.</p></sec><sec id="ab-noi250058-8"><title>Main Outcomes and Measures</title><p>The primary efficacy outcome was 180-day combined death and disability via ordinal modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]). The primary safety outcome was 30-day mortality.</p></sec><sec id="ab-noi250058-9"><title>Results</title><p>Following an independent feasibility analysis prompted by the publication of positive results of a contemporaneous ICH trial, enrollment was stopped early at 236 participants. Overall median (IQR) participant age was 60 (50-70) years, 87 participants (36.9%) were female, 164 (69.5%) had primarily deep bleeds, and 72 (30.5%) had primarily lobar bleeds. Efficacy results of the primary model analysis suggested lack of evidence for the superiority of minimally invasive surgery over medical management (odds ratio [OR], 1.03; 96% CI, 0.62-1.72; <italic toggle="yes">P</italic>&#8201;=&#8201;.45). The adjusted model&#8217;s mean OR was also nonsignificantly greater than 1 (OR, 1.10; 96% CI, 0.66-1.85; <italic toggle="yes">P</italic>&#8201;=&#8201;.35). By 30 days, 11 participants (7.2%) in the surgery group and 8 (9.8%) in the medical management group died (difference, &#8722;2.5%; 95% CI, &#8722;11.7% to 4.8%).</p></sec><sec id="ab-noi250058-10"><title>Conclusions and Relevance</title><p>In the MIND randomized clinical trial, minimally invasive surgery within 72 hours did not significantly reduce 30-day mortality or improve 180-day disability in patients with supratentorial ICH compared to medical management alone.</p></sec><sec id="ab-noi250058-11"><title>Trial Registration</title><p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/study/NCT03342664?cond=NCT03342664&amp;rank=1" ext-link-type="uri">NCT03342664</ext-link></p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>The MIND randomized clinical trial compares the safety and efficacy of minimally invasive surgery with guideline-based medical management alone for spontaneous supratentorial intracerebral hemorrhage.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-NOI250058"><title>Introduction</title><p>Intracerebral hemorrhage (ICH) accounts for 10% to 15% of all strokes and is associated with the highest morbidity and mortality rates of any stroke subtype, with early mortality estimated as high as 30% to 40%.<xref rid="noi250058r1" ref-type="bibr"/> Surgical evacuation is a possible treatment based on the hypothesis that removing blood products alleviates local mass effect and reduces surrounding inflammation and edema, thereby lessening the secondary neurological injury.<xref rid="noi250058r3" ref-type="bibr"/> Trials of conventional surgery and initial trials of minimally invasive surgery (MIS) using stereotactic thrombolysis and drainage established a mortality benefit but failed to demonstrate improved functional outcomes.<xref rid="noi250058r6" ref-type="bibr"/> More recently, the ENRICH (Early Minimally Invasive Removal of Intracerebral Hemorrhage) trial demonstrated higher utility-weighted modified Rankin Scale (mRS) scores in patients with supratentorial ICH undergoing minimally invasive endoscopic evacuation in comparison to those managed medically.<xref rid="noi250058r11" ref-type="bibr"/> These results showed, for the first time, probable functional benefit for MIS in patients with supratentorial lobar ICH. We present the results of MIND (Artemis in the Removal of Intracerebral Hemorrhage), a randomized clinical trial comparing minimally invasive, endoscopic-guided hemorrhage evacuation with the Artemis Neuro Evacuation Device (Penumbra Inc) and standard medical management (MM) with MM alone in patients with supratentorial ICH.</p></sec><sec id="H1-2-NOI250058"><title>Methods</title><sec id="H2-1-NOI250058"><title>Trial Design and Oversight</title><p>MIND was a prospective, open-label, multicenter randomized clinical trial designed to compare the safety and efficacy of MIS with Artemis to MM alone for the treatment of ICH (ClinicalTrials.gov identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/study/NCT03342664?cond=NCT03342664&amp;rank=1" ext-link-type="uri">NCT03342664</ext-link>). The study followed US Food and Drug Administration 21 Code of Federal Regulations (CFR) &#167;812, the Declaration of Helsinki, relevant aspects of the International Organization for Standardization (ISO) 14155:2011, the International Council for Harmonization Good Clinical Practice Recommendations, and all appropriate local regulations. The trial protocol was approved by the institutional review board or ethics committee at each site, and written informed consent was obtained from the patient or an approved delegate prior to trial enrollment. The principal investigators (A.S.A., P.V., and D.J.F.) designed the trial in collaboration with the sponsor (Penumbra Inc), who managed data collection, and Berry Consultants, who developed the adaptive trial methodology and performed the interim, feasibility, and primary data analyses. An independent clinical events committee (CEC) and data safety monitoring board (DSMB) oversaw the study. The CEC evaluated prespecified outcomes for causality and attribution, including neurological serious adverse events (SAEs), device- and procedure-related SAEs, device-related AEs, and all deaths. An independent reviewer assessed all imaging. A blinded certified assessor conducted the 180-day mRS assessments.</p></sec><sec id="H2-2-NOI250058"><title>Eligibility Criteria</title><p>Key inclusion criteria were age between 18 and 80 years, hematoma volume of 20 to 80 mL, premorbid mRS score of 0 to 1, baseline National Institutes of Health Stroke Scale (NIHSS) score of 6 or higher, baseline Glasgow Coma Scale (GCS) score between 5 and 15, and symptom onset less than 24 hours before initial imaging. For the first 2 years of the trial (February 2018 through January 2020), during which 73 study participants (30.9%) were enrolled, a stability scan confirming hemostasis at least 6 hours after initial imaging was mandated. Protocol B removed this requirement and introduced provisions for excluding patients with severe active infection, kidney failure, those receiving direct factor Xa inhibitors, and those presenting with primary thalamic ICH. Additional details are available in the trial protocol in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p></sec><sec id="H2-3-NOI250058"><title>Randomization and Trial Procedures</title><p>Eligible patients were randomized 2:1 to either MIS or MM. The treatment allocation was balanced by the Hemphill score<xref rid="noi250058r13" ref-type="bibr"/> (0-2 or 3-4) and hemorrhage location (primarily lobar vs primarily deep, as determined by the investigator) and involved a minimization algorithm implemented via an interactive web response system. Participants randomized to the control arm received MM for ICH as determined by the treating team and based on current American Heart Association/European Stroke Organization guidelines.<xref rid="noi250058r1" ref-type="bibr"/> Participants randomized to the MIS arm underwent MIS within 72 hours of ictus and received MM. MIS was performed under general anesthesia through a burr hole with a suitably sized endoscopy sheath under direct neuroendoscopic visualization (eFigure 1 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 2</xref>) using any commercially available cranial navigation system. Sites were instructed to choose a technically feasible trajectory to access the longest axis of the hematoma while minimizing damage to healthy brain tissue (see protocol section 6.7.4 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec><sec id="H2-4-NOI250058"><title>Baseline Characteristics</title><p>Baseline characteristics, including age, sex, race, ethnicity, comorbidities, and premorbid mRS, GCS, and NIHSS scores, were recorded by trial investigators from a review of medical records. Sex was classified using a set of binary response options (male/female). Race and ethnicity data were not reportable for European Union sites. The hematoma location was defined by the site investigators and then measured using an ABC/2 formula to determine study inclusion.<xref rid="noi250058r13" ref-type="bibr"/> The independent core laboratory performed hand-traced segmented ICH volume reconstruction and ABC/2 methods to quantify ICH volumes.</p></sec><sec id="H2-5-NOI250058"><title>Outcomes</title><p>The primary efficacy outcome was combined disability and death, assessed by the ordinal mRS at 180 days (range, 0-6, with a score of 0 indicating no deficit and 6 indicating death). The primary safety outcome was mortality within 30 days. Secondary efficacy outcomes reported here include utility-weighted mRS score (range, 0-1, with higher scores indicating better outcomes, according to patients&#8217; assessment; namely, 1.0 for mRS level 0; 0.91 for mRS level 1; 0.76 for mRS level 2; 0.65 for mRS level 3; 0.33 for mRS level 4; 0 for mRS level 5; and 0 for mRS level 6),<xref rid="noi250058r14" ref-type="bibr"/> dichotomized mRS score (&#8804;3 and &#8804;2) at 180 days, procedure time, and length of intensive care unit (ICU) and hospital stay (statistical analysis plan section 10.2 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 1</xref>). Exploratory data included in this report are ordinal mRS at 30 and 90 days and location-specific (deep vs lobar) subgroup analyses (protocol section 6 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec><sec id="H2-6-NOI250058"><title>Statistical Analysis</title><p>The study design allowed for an early end to enrollment for either predicted success or futility based on prespecified interim rules. Interim analyses were scheduled after 200 participants were enrolled and after every 50 participants following that point (adaptive design plan in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 1</xref>). The primary analysis was a proportional odds logistic regression model of the primary efficacy outcome of 180-day ordinal mRS on the intent-to-treat (ITT) population. The model included estimated effects, 2-sided 96% confidence intervals, and 1-sided <italic toggle="yes">P</italic> values. One-sided <italic toggle="yes">P</italic> values were used since MIS superiority over MM was the primary alternative hypothesis, and a 0.02 threshold was used to maintain an overall 1-sided error rate of 0.025%. The proportional odds assumption was visually assessed based on a series of binary logistic regression models (all of the 96% confidence intervals for the odds ratios [ORs] had some overlap supporting the appropriateness of the model). Secondary and exploratory efficacy analyses used the per-protocol (PP) population and 2-sided 95% confidence intervals. All safety analyses used the as-treated (AT) population and 2-sided 95% confidence intervals. <italic toggle="yes">P</italic> values for subgroup or nonprimary efficacy end point comparisons were not provided because the study was not powered for these comparisons. The confidence intervals for descriptive statistics were based on Hodges-Lehmann estimations for differences in medians and the Fisher exact test for categorical differences. The interval widths for the secondary and exploratory analyses have not been adjusted for multiple comparisons. Across all populations and analysis models, mRS scores of 5 and 6 were collapsed into a single category. Missing mRS values were multiply imputed according to the posterior median from a longitudinal model using the last available measurement. Berry Consultants performed the primary efficacy outcome analysis using R version 4.3.3 (R Foundation). All other analyses and figures were performed by Penumbra using SAS version 9.4 (SAS Institute).</p></sec></sec><sec id="H1-3-NOI250058"><title>Results</title><sec id="H2-7-NOI250058"><title>Enrollment and Early Stoppage</title><p>Between February 6, 2018, and August 28, 2023, a total of 4066 patients at 32 institutions (from Austria, Canada, Germany, and the US) were screened for eligibility. The most common reasons for screen failure were ICH volume outside the 20 to 80 mL range (963 of 3746 exclusions [25.7%]) and patient age outside the 18 to 80 year range (588 [15.7%]). The first and only interim analysis occurred in November 2022, with 200 patients enrolled. This analysis did not meet predefined stopping criteria; thus, enrollment continued based on the DSMB recommendation.</p><p>In early 2023, the ENRICH trial reported an overall functional benefit for MIS in patients with lobar ICH.<xref rid="noi250058r11" ref-type="bibr"/> These outcomes led to a loss of equipoise among the MIND investigators and a reluctance to continue randomizing patients with lobar ICH. Following DSMB input, MIND stopped randomizing patients in the primarily lobar cohort. A subsequent feasibility analysis, developed and conducted by an independent statistician group (Berry Consultants), determined&#8212;based on the probability criterion set prior to the analysis&#8212;that there was a low probability of showing a statistical difference between study arms if only patients with primarily deep hemorrhages were randomized moving forward. When the results of this analysis were presented to global principal investigators and the study sponsor, a decision was made to stop MIND enrollment on October 11, 2023. Follow-up visits continued for patients already enrolled in the trial. The current analysis reports on data through 180 days.</p></sec><sec id="H2-8-NOI250058"><title>Patient Characteristics</title><p>The final ITT population comprised 236 participants randomly assigned to the 2 study groups: 154 to receive MIS and 82 to receive standard MM alone (<xref rid="noi250058f1" ref-type="fig">Figure 1</xref>). ITT participants had a median (IQR) age of 60 (50-70) years, a median (IQR) baseline NIHSS score of 18 (14-22), 190 (80.5%) presented a Hemphill score of 0 to 2, and 87 (36.9%) were female. Overall, 1 participant (0.4%) was American Indian or Alaska Native, 23 participants (9.7%) were Asian, 37 (15.7%) were Black or African American, 147 (62.3%) were White, 4 (1.7%) were of other race (without details specified per electronic medical records/case report forms), 2 (0.8%) were more than 1 race, 5 (2.1%) were of unknown race, and 17 (7.2%) did not report race; 31 participants (13.1%) had Hispanic or Latino ethnicity (<xref rid="noi250058t1" ref-type="table">Table 1</xref>; eTable 1 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p><fig position="float" id="noi250058f1" fig-type="figure" orientation="portrait"><label>Figure 1. </label><caption><title>Screening, Allocation, Follow-Up, and Analysis</title><p>The intention-to-treat population comprised all randomized participants. The per-protocol population included participants who received the allocated treatment without inclusion or exclusion violations. The as-treated population comprised participants according to the actual treatment received. Randomization schedule violations occurred in 4 participants (these included 2 treatment crossovers).</p><p><sup>a</sup>One participant was randomized to minimally invasive surgery (MIS) but received medical management (MM) treatment. This participant was analyzed as MIS in the intent-to-treat (ITT) population and MM in the as-treated (AT) population.</p><p><sup>b</sup>Another participant was randomized to MM but received MIS treatment. This participant was analyzed as MM in the ITT population and MIS in the AT population. Two more participants were randomized to MIS but withdrew consent before MIS treatment. These participants were analyzed as MIS in the ITT analysis and excluded from the AT analysis.</p></caption><graphic position="float" orientation="portrait" xlink:href="jamaneurol-e253151-g001.jpg"/></fig><table-wrap position="float" id="noi250058t1" orientation="portrait"><label>Table 1. </label><caption><title>Baseline Characteristics</title></caption><table frame="hsides" rules="groups"><col width="45.38%" span="1"/><col width="19.81%" span="1"/><col width="15.86%" span="1"/><col width="18.95%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">No./total No. (%)<xref rid="noi250058t1n1" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">All participants (N&#8201;=&#8201;236)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">MIS (n&#8201;=&#8201;154)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">MM (n&#8201;=&#8201;82)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, median (IQR), y</td><td valign="top" align="left" rowspan="1" colspan="1">60 (50-70)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (52-69)</td><td valign="top" align="left" rowspan="1" colspan="1">60 (48-70)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex<xref rid="noi250058t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">87/236 (36.9)</td><td valign="top" align="left" rowspan="1" colspan="1">55/154 (35.7)</td><td valign="top" align="left" rowspan="1" colspan="1">32/82 (39.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">149/236 63.1)</td><td valign="top" align="left" rowspan="1" colspan="1">99/154 (64.3)</td><td valign="top" align="left" rowspan="1" colspan="1">50/82 (61.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race<xref rid="noi250058t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> American Indian or Alaska Native</td><td valign="top" align="left" rowspan="1" colspan="1">1/236 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">1/154 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0/82</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Asian</td><td valign="top" align="left" rowspan="1" colspan="1">23/236 (9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">12/154 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">11/82 (13.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black or African American</td><td valign="top" align="left" rowspan="1" colspan="1">37/236 (15.7)</td><td valign="top" align="left" rowspan="1" colspan="1">23/154 (14.9)</td><td valign="top" align="left" rowspan="1" colspan="1">14/82 (17.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Native Hawaiian or Other Pacific Islander</td><td valign="top" align="left" rowspan="1" colspan="1">0/236</td><td valign="top" align="left" rowspan="1" colspan="1">0/154</td><td valign="top" align="left" rowspan="1" colspan="1">0/82</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td><td valign="top" align="left" rowspan="1" colspan="1">147/236 (62.3)</td><td valign="top" align="left" rowspan="1" colspan="1">102/154 (66.2)</td><td valign="top" align="left" rowspan="1" colspan="1">45/82 (54.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref rid="noi250058t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">4/236 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3/154 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1/82 (1.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> More than 1 race</td><td valign="top" align="left" rowspan="1" colspan="1">2/236 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2/154 (1.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0/82</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unknown</td><td valign="top" align="left" rowspan="1" colspan="1">5/236 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1/154 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">4/82 (4.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Not reported</td><td valign="top" align="left" rowspan="1" colspan="1">17/236 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1">10/154 (6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">7/82 (8.5)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ethnicity<xref rid="noi250058t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic or Latino</td><td valign="top" align="left" rowspan="1" colspan="1">31/236 (13.1)</td><td valign="top" align="left" rowspan="1" colspan="1">9/82 (11.0)</td><td valign="top" align="left" rowspan="1" colspan="1">22/154 (14.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Not Hispanic or Latino</td><td valign="top" align="left" rowspan="1" colspan="1">176/236 (74.6)</td><td valign="top" align="left" rowspan="1" colspan="1">115/154 (74.7)</td><td valign="top" align="left" rowspan="1" colspan="1">61/82 (74.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unknown</td><td valign="top" align="left" rowspan="1" colspan="1">4/236 (1.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3/82 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1/154 (0.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Not reported</td><td valign="top" align="left" rowspan="1" colspan="1">25/236 (10.6)</td><td valign="top" align="left" rowspan="1" colspan="1">9/82 (11.0)</td><td valign="top" align="left" rowspan="1" colspan="1">16/154 (10.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Historical mRS</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 0-1</td><td valign="top" align="left" rowspan="1" colspan="1">235/236 (99.6)</td><td valign="top" align="left" rowspan="1" colspan="1">154/154 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">81/82 (98.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &gt;1</td><td valign="top" align="left" rowspan="1" colspan="1">1/236 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0/154</td><td valign="top" align="left" rowspan="1" colspan="1">1/82 (1.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Time from stroke symptom onset to time of randomization, median (IQR) [range], h</td><td valign="top" align="left" rowspan="1" colspan="1">20 (13-30) [2-69]</td><td valign="top" align="left" rowspan="1" colspan="1">22 (14-31) [3-64]</td><td valign="top" align="left" rowspan="1" colspan="1">19.5 (12-28) [2-69]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">NIHSS score at baseline, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (14-22)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (14-22)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (15-22)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Hemphill score at randomization<xref rid="noi250058t1n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 0-2</td><td valign="top" align="left" rowspan="1" colspan="1">190/236 (80.5)</td><td valign="top" align="left" rowspan="1" colspan="1">123/154 (79.9)</td><td valign="top" align="left" rowspan="1" colspan="1">67/82 (81.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3-4</td><td valign="top" align="left" rowspan="1" colspan="1">46/236 (19.5)</td><td valign="top" align="left" rowspan="1" colspan="1">31/154 (20.1)</td><td valign="top" align="left" rowspan="1" colspan="1">15/82 (18.3)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">GCS score at randomization</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3-4</td><td valign="top" align="left" rowspan="1" colspan="1">0/236</td><td valign="top" align="left" rowspan="1" colspan="1">0/154</td><td valign="top" align="left" rowspan="1" colspan="1">0/82</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 5-12</td><td valign="top" align="left" rowspan="1" colspan="1">130/236 (55.1)</td><td valign="top" align="left" rowspan="1" colspan="1">86/154 (55.8)</td><td valign="top" align="left" rowspan="1" colspan="1">44/82 (53.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 13-15</td><td valign="top" align="left" rowspan="1" colspan="1">106/236 (44.9)</td><td valign="top" align="left" rowspan="1" colspan="1">68/154 (44.2)</td><td valign="top" align="left" rowspan="1" colspan="1">38/82 (46.3)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Location of the hemorrhage, per investigator<xref rid="noi250058t1n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Primarily deep</td><td valign="top" align="left" rowspan="1" colspan="1">164/236 (69.5)</td><td valign="top" align="left" rowspan="1" colspan="1">105/154 (68.2)</td><td valign="top" align="left" rowspan="1" colspan="1">59/82 (72.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Basal ganglia</td><td valign="top" align="left" rowspan="1" colspan="1">156/164 (95.1)</td><td valign="top" align="left" rowspan="1" colspan="1">99/105 (94.3)</td><td valign="top" align="left" rowspan="1" colspan="1">57/59 (96.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Caudate</td><td valign="top" align="left" rowspan="1" colspan="1">0/164</td><td valign="top" align="left" rowspan="1" colspan="1">0/105</td><td valign="top" align="left" rowspan="1" colspan="1">0/59</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Thalamus</td><td valign="top" align="left" rowspan="1" colspan="1">1/164 (0.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1/105 (1.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0/59</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> External capsule</td><td valign="top" align="left" rowspan="1" colspan="1">12/164 (7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">8/105 (7.6)</td><td valign="top" align="left" rowspan="1" colspan="1">4/59 (6.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Primarily lobar</td><td valign="top" align="left" rowspan="1" colspan="1">72/236 (30.5)</td><td valign="top" align="left" rowspan="1" colspan="1">49/154 (31.8)</td><td valign="top" align="left" rowspan="1" colspan="1">23/82 (28.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Frontal</td><td valign="top" align="left" rowspan="1" colspan="1">42/72 (58.3)</td><td valign="top" align="left" rowspan="1" colspan="1">30/49 (61.2)</td><td valign="top" align="left" rowspan="1" colspan="1">12/23 (52.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Parietal</td><td valign="top" align="left" rowspan="1" colspan="1">34/72 (47.2)</td><td valign="top" align="left" rowspan="1" colspan="1">21/49 (42.9)</td><td valign="top" align="left" rowspan="1" colspan="1">13/23 (56.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Temporal</td><td valign="top" align="left" rowspan="1" colspan="1">10/72 (13.9)</td><td valign="top" align="left" rowspan="1" colspan="1">7/49 (14.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3/23 (13.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Occipital</td><td valign="top" align="left" rowspan="1" colspan="1">6/72 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">4/49 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">2/23 (8.7)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">ICH volume, median (IQR), mL</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Per investigator (ABC/2)<xref rid="noi250058t1n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">39 (29-55)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (30-55)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (29-54)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Per core laboratory</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hand-traced, PP population<xref rid="noi250058t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">34.8 (25.1-49.0)</td><td valign="top" align="left" rowspan="1" colspan="1">35.7 (24.9-48.7)</td><td valign="top" align="left" rowspan="1" colspan="1">33.8 (25.2-50.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ABC/2<xref rid="noi250058t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">40.7 (26.6-55.8)</td><td valign="top" align="left" rowspan="1" colspan="1">40.7 (26.6-56.1)</td><td valign="top" align="left" rowspan="1" colspan="1">41.0 (26.6-54.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">IVH, per core laboratory</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Patients with IVH involvement</td><td valign="top" align="left" rowspan="1" colspan="1">96/236 (40.7)</td><td valign="top" align="left" rowspan="1" colspan="1">65/154 (42.2)</td><td valign="top" align="left" rowspan="1" colspan="1">31/82 (37.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Graeb score, median (IQR)<xref rid="noi250058t1n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">3 (2-6)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (2-5)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (2-7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Graeb score &#8805;5<xref rid="noi250058t1n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">34/96 (35.4)</td><td valign="top" align="left" rowspan="1" colspan="1">21/65 (32.3)</td><td valign="top" align="left" rowspan="1" colspan="1">13/31 (41.9)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline medications</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anticoagulant</td><td valign="top" align="left" rowspan="1" colspan="1">15/236 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">13/154 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2/82 (2.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antiplatelet</td><td valign="top" align="left" rowspan="1" colspan="1">41/236 (17.4)</td><td valign="top" align="left" rowspan="1" colspan="1">32/154 (20.8)</td><td valign="top" align="left" rowspan="1" colspan="1">9/82 (11.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hematologic modifiers</td><td valign="top" align="left" rowspan="1" colspan="1">16/236 (6.8)</td><td valign="top" align="left" rowspan="1" colspan="1">9/154 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">7/82 (8.5)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Medical history, general</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hypertension</td><td valign="top" align="left" rowspan="1" colspan="1">191/236 (80.9)</td><td valign="top" align="left" rowspan="1" colspan="1">127/154 (82.5)</td><td valign="top" align="left" rowspan="1" colspan="1">64/82 (78.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diabetes</td><td valign="top" align="left" rowspan="1" colspan="1">61/236 (25.8)</td><td valign="top" align="left" rowspan="1" colspan="1">43/154 (27.9)</td><td valign="top" align="left" rowspan="1" colspan="1">18/82 (22.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cardiovascular or vascular disease</td><td valign="top" align="left" rowspan="1" colspan="1">50/236 (21.2)</td><td valign="top" align="left" rowspan="1" colspan="1">34/154 (22.1)</td><td valign="top" align="left" rowspan="1" colspan="1">16/82 (19.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Atherosclerosis</td><td valign="top" align="left" rowspan="1" colspan="1">42/236 (17.8)</td><td valign="top" align="left" rowspan="1" colspan="1">26/154 (16.9)</td><td valign="top" align="left" rowspan="1" colspan="1">16/82 (19.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hematologic disorder</td><td valign="top" align="left" rowspan="1" colspan="1">26/236 (11.0)</td><td valign="top" align="left" rowspan="1" colspan="1">14/154 (9.1)</td><td valign="top" align="left" rowspan="1" colspan="1">12/82 (14.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Liver disease</td><td valign="top" align="left" rowspan="1" colspan="1">8/236 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">3/154 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">5/82 (6.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Medical history, neurological</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Headaches or migraines</td><td valign="top" align="left" rowspan="1" colspan="1">54/236 (22.9)</td><td valign="top" align="left" rowspan="1" colspan="1">38/154 (24.7)</td><td valign="top" align="left" rowspan="1" colspan="1">16/82 (19.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Seizures</td><td valign="top" align="left" rowspan="1" colspan="1">12/236 (5.1)</td><td valign="top" align="left" rowspan="1" colspan="1">7/154 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">5/82 (6.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Ischemic stroke</td><td valign="top" align="left" rowspan="1" colspan="1">12/236 (5.1)</td><td valign="top" align="left" rowspan="1" colspan="1">5/154 (3.2)</td><td valign="top" align="left" rowspan="1" colspan="1">7/82 (8.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Transient ischemic attack</td><td valign="top" align="left" rowspan="1" colspan="1">11/236 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">6/154 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">5/82 (6.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Previous hemorrhagic stroke</td><td valign="top" align="left" rowspan="1" colspan="1">10/236 (4.2)</td><td valign="top" align="left" rowspan="1" colspan="1">6/154 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">4/82 (4.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Intracranial surgery</td><td valign="top" align="left" rowspan="1" colspan="1">2/236 (0.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0/154</td><td valign="top" align="left" rowspan="1" colspan="1">2/82 (2.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No pertinent medical history</td><td valign="top" align="left" rowspan="1" colspan="1">8/236 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">6/154 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">2/82 (2.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Use of illicit drugs within last 30 d</td><td valign="top" align="left" rowspan="1" colspan="1">17/236 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1">14/154 (9.1)</td><td valign="top" align="left" rowspan="1" colspan="1">3/82 (3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol abuse within last 6 mo</td><td valign="top" align="left" rowspan="1" colspan="1">28/236 (11.9)</td><td valign="top" align="left" rowspan="1" colspan="1">17/154 (11.0)</td><td valign="top" align="left" rowspan="1" colspan="1">11/82 (13.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tobacco use</td><td valign="top" align="left" rowspan="1" colspan="1">85/236 (36.0)</td><td valign="top" align="left" rowspan="1" colspan="1">56/154 (36.4)</td><td valign="top" align="left" rowspan="1" colspan="1">29/82 (35.4)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: GCS, Glasgow Coma Scale (range, 3-15, with lower scores indicating a more severe depression of mental status [ie, a score of 15 corresponds to fully conscious state and 3 corresponds to deep coma]); ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; MIS, minimally invasive surgery; MM, medical management; mRS, modified Rankin Scale score (range, 0-6, with 0 indicating no deficit and 6 indicating death); NIHSS, the National Institutes of Health Stroke Scale (range, 0-42, with higher scores indicating more severe neurologic deficit); PP, per protocol.</p><fn id="noi250058t1n1"><label>
<sup>a</sup>
</label><p>Data for intention-to-treat population (N&#8201;=&#8201;236) unless indicated otherwise.</p></fn><fn id="noi250058t1n2"><label>
<sup>b</sup>
</label><p>Data on sex, race, and ethnicity were collected by trial investigators from a review of medical records and classified using set response options. Data on race and ethnicity were collected only for the participants in the US and Canada, as European Union laws prohibit the collection of this information.</p></fn><fn id="noi250058t1n3"><label>
<sup>c</sup>
</label><p>Listed as &#8220;Other&#8221; without details specified per electronic medical records/case report forms.</p></fn><fn id="noi250058t1n4"><label>
<sup>d</sup>
</label><p>Hemphill scores (also known as ICH scores) range from 0 to 5, with higher scores indicating more severe hemorrhage and a poorer prognosis.</p></fn><fn id="noi250058t1n5"><label>
<sup>e</sup>
</label><p>Provided by the investigator at the final screening/baseline, calculated using the ABC/2 formula.<xref rid="noi250058r13" ref-type="bibr"/> Participants may have &#8805;1 hemorrhage sublocation, but only 1 main hemorrhage location (deep vs lobar).</p></fn><fn id="noi250058t1n6"><label>
<sup>f</sup>
</label><p>Provided by the core laboratory personnel who interpreted and adjudicated the neuroimaging, calculated using either hand-traced method or ABC/2 formula<xref rid="noi250058r13" ref-type="bibr"/> as indicated.</p></fn><fn id="noi250058t1n7"><label>
<sup>g</sup>
</label><p>Graeb scores range from 0 to 32, with higher scores indicating a more severe filling (ie, a score of 32 indicates every compartment is filled with blood and expanded).</p></fn></table-wrap-foot></table-wrap><p>Of 236 participants, 164 (69.5%) had primarily deep hemorrhages and 72 (30.5%) had primarily lobar hemorrhages. Basal ganglia, the most common sublocation for deep hemorrhages, were reported in 156 of 164 participants (95.1%) (<xref rid="noi250058t1" ref-type="table">Table 1</xref>). At randomization, the median (IQR) baseline ICH volume (principal investigator&#8211;determined via the ABC/2 method) was 39 (29-55) mL. More than a third of the ITT population (96 of 236 [40.7%]) had intraventricular hemorrhage; of these, 34 (35.4%) (per core laboratory) had a Graeb score<xref rid="noi250058r15" ref-type="bibr"/> of 5 or higher. The median (IQR) time from symptom onset to randomization was 20 (13-30) hours. Overall, trial groups were similar in demographics and baseline characteristics, including ICH volume and stroke severity at presentation (<xref rid="noi250058t1" ref-type="table">Table 1</xref>).</p></sec><sec id="H2-9-NOI250058"><title>Technical Outcomes</title><p>In the PP population, the median (IQR) time from symptom onset to MIS was 27.5 (21-46) hours; 55 of 142 MIS patients (38.7%) underwent surgery within 24 hours or less from symptom onset. Following MIS, median (IQR) ICH volume was reduced by 80.7% (64.2%-92.3%) to 6.3 (2.9-14.0) mL, with 114 of 144 participants (79.2%) having residual hemorrhage volumes of 15 mL or less (<xref rid="noi250058t2" ref-type="table">Table 2</xref>). On average, deep hemorrhages were smaller yet took longer to evacuate than lobar hemorrhages; nevertheless, similar evacuation outcomes were observed for the primarily deep and primarily lobar cohorts (eTable 2 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 2</xref>). The rates of external ventricular drain placement during MIS or within 24 hours of the procedure, conversion to craniotomy, and significant procedural hemorrhage requiring cauterization were 12.5% (18 of 144), 1.4% (2 of 144), and 6.3% (9 of 144), respectively.</p><table-wrap position="float" id="noi250058t2" orientation="portrait"><label>Table 2. </label><caption><title>Technical and Secondary Efficacy Outcomes<xref rid="noi250058t2n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="38.26%" span="1"/><col width="17.98%" span="1"/><col width="14.24%" span="1"/><col width="29.52%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Outcome</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">MIS</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">MM</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">MIS&#8201;&#8722;&#8201;MM difference (95% CI) or OR (95% CI)<xref rid="noi250058t2n2" ref-type="table-fn"><sup>b</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Process times</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Time from stroke symptom onset to procedure, median (IQR), h<xref rid="noi250058t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">27.5 (21 to 46)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8804;12 h, No./total No. (%)</td><td valign="top" align="left" rowspan="1" colspan="1">15/142 (10.6)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8804;24 h, No./total No. (%)</td><td valign="top" align="left" rowspan="1" colspan="1">55/142 (38.7)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">ICH volume, per core laboratory (hand-traced)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> End of treatment ICH volume, median (IQR), mL</td><td valign="top" align="left" rowspan="1" colspan="1">6.3 (2.9 to 14.0)</td><td valign="top" align="left" rowspan="1" colspan="1">32.8 (21.3 to 45.0)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;23.2 (&#8722;27.0 to &#8722;19.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> End of treatment &lt;15 mL, No./total No. (%)</td><td valign="top" align="left" rowspan="1" colspan="1">114/144 (79.2)</td><td valign="top" align="left" rowspan="1" colspan="1">3/74 (4.1)</td><td valign="top" align="left" rowspan="1" colspan="1">75.1% (65.6% to 82.6%)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Absolute change from baseline to end of treatment, median (IQR), mL</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;25.1 (&#8722;40.0 to &#8722;16.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.8 (&#8722;5.0 to 2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;24.9 (&#8722;28.7 to &#8722;21.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Reduction in ICH volume by mL, median (IQR), %<xref rid="noi250058t2n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">80.7 (64.2 to 92.3)</td><td valign="top" align="left" rowspan="1" colspan="1">2.4 (&#8722;12.0 to 7.6)</td><td valign="top" align="left" rowspan="1" colspan="1">75.5 (69.8 to 81.2)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Secondary outcomes</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Procedure duration, median (IQR), min<xref rid="noi250058t2n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">33.5 (20.0 to 55.0)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Utility-weighted mRS at 180 days, mean (SD)<xref rid="noi250058t2n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.41 (0.29)</td><td valign="top" align="left" rowspan="1" colspan="1">0.38 (0.31)</td><td valign="top" align="left" rowspan="1" colspan="1">0.04 (&#8722;0.04 to 0.12)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> mRS &#8804;3 at 180 d, No./total No. (%)<xref rid="noi250058t2n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">53/144 (36.8)</td><td valign="top" align="left" rowspan="1" colspan="1">29/78 (37.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.58 to 1.84)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> mRS &#8804;2 at 180 d, No./total No. (%)<xref rid="noi250058t2n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">24/144 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13/78 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1.05 (0.49 to 2.22)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Length of hospital stay, median (IQR), d<xref rid="noi250058t2n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">15 (10 to 22)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (9 to 27)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2 (&#8722;5 to 1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Time in the ICU, median (IQR), d<xref rid="noi250058t2n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.8 to 9.5)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (3.5 to 12.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.5 (&#8722;2.0 to 1.0)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ICH, intracerebral hemorrhage; ICU, intensive care unit; MIS, minimally invasive surgery; MM, medical management; mRS, modified Rankin Scale; NA, not applicable; OR, odds ratio.</p><fn id="noi250058t2n1"><label>
<sup>a</sup>
</label><p>Length of hospital stay is defined as time from randomization and discharge.</p></fn><fn id="noi250058t2n2"><label>
<sup>b</sup>
</label><p>Confidence intervals were calculated by the Fisher exact test for binary results, Wald method for ORs, Hodges-Lehmann estimation of location shift for the difference in the median, and analysis of covariance controlled by strata for the utility-weighted mRS difference.</p></fn><fn id="noi250058t2n3"><label>
<sup>c</sup>
</label><p>Beginning of the procedure is defined as the time of initial sheath placement.</p></fn><fn id="noi250058t2n4"><label>
<sup>d</sup>
</label><p>For the MIS group, this is equivalent to the evacuation rate, which is the percentage of reduction in ICH volume from baseline to completion of the surgery. ICH volume data reported by the core imaging laboratory was calculated using segmented volume reconstruction (ie, hand-traced method).</p></fn><fn id="noi250058t2n5"><label>
<sup>e</sup>
</label><p>Procedure duration is defined as time from initial sheath placement to final sheath removal.</p></fn><fn id="noi250058t2n6"><label>
<sup>f</sup>
</label><p>The utility-weighted mRS ranges from 0 to 1, with higher scores indicating better outcomes, according to patients&#8217; assessment (namely, 1.0 for mRS level 0, 0.91 for mRS level 1, 0.76 for mRS level 2, 0.65 for mRS level 3, 0.33 for mRS level 4, 0 for mRS level 5, and 0 for mRS level 6), all as reported by Chaisinanunkul and colleagues in 2015.<xref rid="noi250058r14" ref-type="bibr"/></p></fn><fn id="noi250058t2n7"><label>
<sup>g</sup>
</label><p>Weighted and dichotomized mRS analyses were also adjusted for stratification variables (Hemphill score 0-2 vs 3-4 and ICH location).</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-10-NOI250058"><title>Primary Efficacy Outcome</title><p>There were 184 participants with mRS data at 180 days and 52 with imputed mRS scores (32 assessed outside the protocol window and 20 not evaluated). No statistically significant difference in ordinal mRS at 180 days was observed between the MIS and MM groups for either the unadjusted ITT population (OR, 1.03; 96% CI, 0.62-1.72; <italic toggle="yes">P</italic>&#8201;=&#8201;.45) or adjusted by strata ITT population (OR, 1.10; 96% CI, 0.66-1.85; <italic toggle="yes">P</italic>&#8201;=&#8201;.35). In the PP population, the unadjusted OR was 1.20 (96% CI, 0.71-2.03; <italic toggle="yes">P</italic>&#8201;=&#8201;.24), and after adjusting by strata, the OR was 1.29 (96% CI, 0.76-2.20; <italic toggle="yes">P</italic>&#8201;=&#8201;.16). Primary efficacy results by the analysis model and study population are shown in <xref rid="noi250058f2" ref-type="fig">Figure 2</xref>A.</p><fig position="float" id="noi250058f2" fig-type="figure" orientation="portrait"><label>Figure 2. </label><caption><title>Forest Plot: Ordinal Modified Rankin Scale (mRS) Scores</title><p>A, Primary efficacy outcome (ordinal mRS at 180 days) for intention-to-treat (ITT) and per-protocol (PP) populations analyzed using primary and secondary models. B, Ordinal mRS at 30, 90, and 180 days for the PP population (overall, deep, and lobar cohorts) adjusted for baseline monitored Hemphill score and intracerebral hemorrhage location. Data in panels A and B are shown as the odds ratios (ORs) for minimally invasive surgery (MIS) vs medical management (MM). Note that the pronounced treatment benefit of MIS at 30 days diminished by 90- and 180-day follow-up. Missing values (or data collected outside the protocol window) were imputed by a posterior median from a longitudinal model.</p></caption><graphic position="float" orientation="portrait" xlink:href="jamaneurol-e253151-g002.jpg"/></fig></sec><sec id="H2-11-NOI250058"><title>Secondary Efficacy Outcomes</title><p>The utility-weighted mRS<xref rid="noi250058r14" ref-type="bibr"/> scores at 180 days (0.41 in the MIS group and 0.38 in the MM group) were comparable between the study arms (difference, 0.04; 95% CI, &#8722;0.04 to 0.12) (<xref rid="noi250058t2" ref-type="table">Table 2</xref>). Dichotomized mRS scores (&#8804;3 and &#8804;2) at 180 days were also similar between MIS (OR, 1.03; 95% CI, 0.58-1.84) and MM groups (OR, 1.03; 95% CI, 0.58-1.84) (<xref rid="noi250058t2" ref-type="table">Table 2</xref>). Length of stay in the ICU (difference, &#8722;0.5 days; 95% CI, &#8722;2 to 1) and hospital (difference, &#8722;2 days; 95% CI, &#8722;5 to 1) directionally favored MIS over MM (<xref rid="noi250058t2" ref-type="table">Table 2</xref>), but the effects were not statistically significant in this dataset.</p></sec><sec id="H2-12-NOI250058"><title>Primary Safety Outcome and Overall Mortality</title><p>Among the AT population, 11 of 152 MIS patients (7.2%) and 8 of 82 MM patients (9.8%) died within 30 days (primary safety outcome; difference, &#8722;2.5%; 95% CI, &#8722;11.7% to 4.8%). At 180 days, 20 of 152 MIS patients (13.2%) and 15 of 82 MM patients (18.3%) died (difference, &#8722;5.1%; 95% CI, &#8722;16.1% to 4.5%) (<xref rid="noi250058t3" ref-type="table">Table 3</xref>). A prespecified Kaplan-Meier survival analysis likewise demonstrated a similar relative risk of death between the study arms through 30 days (MIS vs MM, log-rank <italic toggle="yes">P</italic>&#8201;=&#8201;.51) (eFigure 2 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 2</xref>). When stratified by the ICH location, the Kaplan-Meier analysis showed separation of the treatments for the primarily lobar but not the deep cohort (eFigure 3 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p><table-wrap position="float" id="noi250058t3" orientation="portrait"><label>Table 3. </label><caption><title>Safety Outcomes<xref rid="noi250058t3n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="30.37%" span="1"/><col width="16.91%" span="1"/><col width="15.95%" span="1"/><col width="13.39%" span="1"/><col width="23.38%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">No./total No. (%)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">MIS&#8201;&#8722;&#8201;MM difference (95% CI), %</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">All participants</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">MIS</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">MM</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Summary of death events<xref rid="noi250058t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Death within 7 d</td><td valign="top" align="left" rowspan="1" colspan="1">2/234 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1/152 (0.7)</td><td valign="top" align="left" rowspan="1" colspan="1">1/82 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;0.6 (&#8722;6.1 to 2.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Death within 30 d (primary safety outcome)</td><td valign="top" align="left" rowspan="1" colspan="1">19/234 (8.1)</td><td valign="top" align="left" rowspan="1" colspan="1">11/152 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1">8/82 (9.8)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;2.5 (&#8722;11.7 to 4.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Death within 180 d</td><td valign="top" align="left" rowspan="1" colspan="1">35/234 (15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">20/152 (13.2)</td><td valign="top" align="left" rowspan="1" colspan="1">15/82 (18.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;5.1 (&#8722;16.1 to 4.5)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Adverse events<xref rid="noi250058t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Adverse events within 180 d</td><td valign="top" align="left" rowspan="1" colspan="1">199/234 (85.0)</td><td valign="top" align="left" rowspan="1" colspan="1">126/152 (82.9)</td><td valign="top" align="left" rowspan="1" colspan="1">73/82 (89.0)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;6.1 (&#8722;14.9 to 4.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Serious adverse events within 180 d</td><td valign="top" align="left" rowspan="1" colspan="1">136/234 (58.1)</td><td valign="top" align="left" rowspan="1" colspan="1">80/152 (52.6)</td><td valign="top" align="left" rowspan="1" colspan="1">56/82 (68.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8722;15.7 (&#8722;28.1 to &#8722;1.1)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: MIS, minimally invasive surgery; MM, medical management.</p><fn id="noi250058t3n1"><label>
<sup>a</sup>
</label><p>Data for as-treated population (N&#8201;=&#8201;234). Confidence intervals were calculated by the Fisher exact test for binary results.</p></fn><fn id="noi250058t3n2"><label>
<sup>b</sup>
</label><p>Evaluated per the clinical events committee.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-13-NOI250058"><title>AEs</title><p>Within 180 days, fewer SAEs were reported in MIS (80 of 152 [52.6%]) compared to MM (56 of 82 [68.3%]) (difference, &#8722;15.7%; 95% CI, &#8722;28.1% to &#8722;1.1%) (<xref rid="noi250058t3" ref-type="table">Table 3</xref>). The primarily lobar and primarily deep bleed cohorts had similar rates of safety events (eTable 3 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p></sec><sec id="H2-14-NOI250058"><title>Exploratory Efficacy Outcomes</title><p>An exploratory analysis of ordinal mRS assessed at different time points (PP population adjusted for strata) suggested improved clinical outcomes 30 days after MIS for the entire population (OR, 4.23; 95% CI, 2.36-7.57), as well as the primarily lobar bleed (OR, 5.30; 95% CI, 1.73-16.20) and primarily deep bleed cohorts (OR, 3.88; 95% CI, 1.96-7.68). However, the benefit of MIS was no longer observed at 90- and 180-day follow-up, although the absolute treatment effect favored MIS (<xref rid="noi250058f2" ref-type="fig">Figure 2</xref>B). This favorable treatment effect at 30 days was attributable to a shift from mRS 5 to 4 in this subpopulation (eFigure 5 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p></sec></sec><sec id="H1-4-NOI250058"><title>Discussion</title><p>The MIND randomized clinical trial did not demonstrate an improvement in functional outcomes at 180 days for patients with supratentorial ICH treated with MIS and MM compared to MM alone. Exploratory efficacy analyses by ICH location also did not provide evidence of a benefit for MIS at 180 days in either cohort.</p><p>The results of MIS suggest an early beneficial effect, as shown by a marked improvement in ordinal mRS scores at 30 days and a reduction in SAEs through 180 days. These positive results, however, were based on exploratory analyses. MIS was not associated with any excess death during the 30-day follow-up. There was no difference in procedural safety between the primarily lobar and the primarily deep cohorts.</p><p>The lack of a functional benefit at 180 days did not appear to be related to technical performance. The treatment group showed an average of approximately 80% reduced ICH volumes after MIS, and 80% of treated patients were left with a residual ICH volume of less than 15 mL after the procedure. The proportion of participants that achieved this target evacuation goal in MIND exceeded those reported in both the ENRICH (72%) and MISTIE III (59%) trials.<xref rid="noi250058r9" ref-type="bibr"/> The vast majority (&gt;98%) of the hemorrhage evacuations in MIND were successfully completed with the MIS technique, with very few patients requiring conversion to craniotomy.</p><p>Recently, the ENRICH study demonstrated improved functional outcomes at 180 days in a cohort of 300 patients with supratentorial ICH treated with trans-sulcal parafasicular MIS.<xref rid="noi250058r11" ref-type="bibr"/> In addition to the differences in the MIS technique (eFigures 1 and 4 in <xref rid="note-NOI250058-1-s" ref-type="supplementary-material">Supplement 2</xref>), several other differences in study design and patient populations may have accounted for the difference in outcomes seen in MIND. First, the ratio of primarily deep to primarily lobar hemorrhages was 70:30 in MIND vs 30:70 in ENRICH. The beneficial effect of MIS in ENRICH was dominated by the primarily lobar group after enrollment in the primarily deep location was halted. Second, in ENRICH, MIS was performed more than 10 hours earlier than in MIND, with median (IQR) times from symptom onset to intervention of 16.8 (10.7-21.3) hours and 27.5 (21-45) hours in ENRICH and MIND, respectively. The beneficial effect of ICH evacuation may be enhanced by early intervention, but the evidence is inconclusive.<xref rid="noi250058r10" ref-type="bibr"/> Third, ICH volumes were larger in ENRICH than in MIND, with median ICH volumes (per core laboratory, ABC/2 method) measuring approximately 55 mL in ENRICH and 41 mL in MIND. While presenting NIHSS scores in MIND and ENRICH were similar, the relatively smaller ICH volumes in MIND may have been reflected by the lower rate of death observed in the MM arm; the 30-day mortality rates were 9.8% in MIND and 18.0% in ENRICH. At the same time, rates of death and poor clinical outcomes were similar in the MIS arms of MIND and ENRICH (7.2% and 9.3%, respectively). Thus, including patients with smaller hemorrhages in MIND may have reduced the magnitude of the absolute treatment effect compared to ENRICH.</p><sec id="H2-15-NOI250058"><title>Limitations</title><p>There are several limitations to this study warranting discussion. First, early stopping led to reduced statistical power to observe true differences between treatment arms. Conclusions drawn from the current analysis should be viewed with consideration for the sample size constraints and the potential influence of confounding variables. Additionally, evaluators performing the 180-day mRS assessment, but not the 30- and 90-day evaluations, were blinded to the treatment received by the patient, adding to the risk of potential bias. Second, patients were enrolled over 5 years (partly overlapping with the COVID-19 pandemic), which may have introduced additional variability and increased the rate of missing follow-up. Third, it can be argued that Black participants were underrepresented, accounting for approximately 1.6-fold greater incidence of ICH in this patient population compared to White individuals.<xref rid="noi250058r1" ref-type="bibr"/> Fourth, in the current report, patients were followed up for 180 days, and longer-term follow-up of this cohort may be informative. Lastly, analyses expanding on traditional clinical definitions by including patient-reported quality of life outcomes would be helpful to provide nuanced context of recovery after ICH.</p></sec></sec><sec id="H1-5-NOI250058"><title>Conclusions</title><p>MIS with the Artemis Neuro Evacuation Device did not result in an improvement in 180-day disability or 30-day mortality rates in patients with spontaneous supratentorial ICH compared to standard MM alone. Excellent technical performance and improved disability at 30 days following MIS were achieved in patients with both deep and lobar ICHs. Based on this positive exploratory evidence, a compelling argument can be made for further study of MIS in supratentorial ICH.</p></sec></body><back><ref-list id="REF-NOI250058"><title>References</title><ref id="noi250058r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Greenberg</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Ziai</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Cordonnier</surname><given-names>C</given-names></string-name>, <etal/>; <collab>American Heart Association/American Stroke Association</collab></person-group>. <article-title>2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: a guideline from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source>. <year>2022</year>;<volume>53</volume>(<issue>7</issue>):<fpage>e282</fpage>-<lpage>e361</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STR.0000000000000407</pub-id><pub-id pub-id-type="pmid">35579034</pub-id></mixed-citation></ref><ref id="noi250058r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ziai</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Badihian</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ullman</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Hemorrhage expansion rates before and after minimally invasive surgery for intracerebral hemorrhage: post hoc analysis of MISTIE II/III</article-title>. <source>Stroke Vasc Intervent Neurol</source>. <year>2024</year>;<volume>0</volume>(<issue>0</issue>):<elocation-id>e001165</elocation-id>. doi:<pub-id pub-id-type="doi">10.1161/SVIN.123.001165</pub-id></mixed-citation></ref><ref id="noi250058r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Zazulia</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Diringer</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Derdeyn</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Powers</surname><given-names>WJ</given-names></string-name></person-group>. <article-title>Progression of mass effect after intracerebral hemorrhage</article-title>. <source>Stroke</source>. <year>1999</year>;<volume>30</volume>(<issue>6</issue>):<fpage>1167</fpage>-<lpage>1173</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.STR.30.6.1167</pub-id><pub-id pub-id-type="pmid">10356094</pub-id></mixed-citation></ref><ref id="noi250058r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Zazulia</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Diringer</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Videen</surname><given-names>TO</given-names></string-name>, <etal/></person-group>. <article-title>Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2001</year>;<volume>21</volume>(<issue>7</issue>):<fpage>804</fpage>-<lpage>810</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00004647-200107000-00005</pub-id><pub-id pub-id-type="pmid">11435792</pub-id></mixed-citation></ref><ref id="noi250058r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wagner</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Xi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hua</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kleinholz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>de Courten-Myers</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Myers</surname><given-names>RE</given-names></string-name></person-group>. <article-title>Early metabolic alterations in edematous perihematomal brain regions following experimental intracerebral hemorrhage</article-title>. <source>J Neurosurg</source>. <year>1998</year>;<volume>88</volume>(<issue>6</issue>):<fpage>1058</fpage>-<lpage>1065</lpage>. doi:<pub-id pub-id-type="doi">10.3171/jns.1998.88.6.1058</pub-id><pub-id pub-id-type="pmid">9609301</pub-id></mixed-citation></ref><ref id="noi250058r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mendelow</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Gregson</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname><given-names>HM</given-names></string-name>, <etal/>; <collab>STICH investigators</collab></person-group>. <article-title>Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage (STICH): a randomised trial</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>365</volume>(<issue>9457</issue>):<fpage>387</fpage>-<lpage>397</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(05)70233-6</pub-id><pub-id pub-id-type="pmid">15680453</pub-id></mixed-citation></ref><ref id="noi250058r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mendelow</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Gregson</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Rowan</surname><given-names>EN</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Gholkar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>PM</given-names></string-name>; <collab>STICH II Investigators</collab></person-group>. <article-title>Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial</article-title>. <source>Lancet</source>. <year>2013</year>;<volume>382</volume>(<issue>9890</issue>):<fpage>397</fpage>-<lpage>408</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(13)60986-1</pub-id><pub-id pub-id-type="pmid">23726393</pub-id><pub-id pub-id-type="pmcid">PMC3906609</pub-id></mixed-citation></ref><ref id="noi250058r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hanley</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Muschelli</surname><given-names>J</given-names></string-name>, <etal/>; <collab>MISTIE Investigators</collab></person-group>. <article-title>Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial</article-title>. <source>Lancet Neurol</source>. <year>2016</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1228</fpage>-<lpage>1237</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(16)30234-4</pub-id><pub-id pub-id-type="pmid">27751554</pub-id><pub-id pub-id-type="pmcid">PMC5154627</pub-id></mixed-citation></ref><ref id="noi250058r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hanley</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Rosenblum</surname><given-names>M</given-names></string-name>, <etal/>; <collab>MISTIE III Investigators</collab></person-group>. <article-title>Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial</article-title>. <source>Lancet</source>. <year>2019</year>;<volume>393</volume>(<issue>10175</issue>):<fpage>1021</fpage>-<lpage>1032</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(19)30195-3</pub-id><pub-id pub-id-type="pmid">30739747</pub-id><pub-id pub-id-type="pmcid">PMC6894906</pub-id></mixed-citation></ref><ref id="noi250058r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Scaggiante</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Mocco</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kellner</surname><given-names>CP</given-names></string-name></person-group>. <article-title>Minimally invasive surgery for intracerebral hemorrhage</article-title>. <source>Stroke</source>. <year>2018</year>;<volume>49</volume>(<issue>11</issue>):<fpage>2612</fpage>-<lpage>2620</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.118.020688</pub-id><pub-id pub-id-type="pmid">30355183</pub-id></mixed-citation></ref><ref id="noi250058r11"><label>11</label><mixed-citation publication-type="confproc"><person-group><string-name name-style="western"><surname>Pradilla</surname><given-names>G</given-names></string-name></person-group>. Efficacy and safety of early minimally invasive removal of intracerebral hemorrhage (ENRICH): a multi-centered randomized adaptive trial. Presented at: American Association of Neurological Surgeons; April 21-24, <year>2023</year>; Los Angeles, California.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2023.1126958</pub-id><pub-id pub-id-type="pmcid">PMC10061000</pub-id><pub-id pub-id-type="pmid">37006503</pub-id></mixed-citation></ref><ref id="noi250058r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Pradilla</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ratcliff</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>AJ</given-names></string-name>, <etal/>; <collab>ENRICH trial investigators</collab>; <collab>ENRICH Trial Investigators</collab></person-group>. <article-title>Trial of early minimally invasive removal of intracerebral hemorrhage</article-title>. <source>N Engl J Med</source>. <year>2024</year>;<volume>390</volume>(<issue>14</issue>):<fpage>1277</fpage>-<lpage>1289</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2308440</pub-id><pub-id pub-id-type="pmid">38598795</pub-id></mixed-citation></ref><ref id="noi250058r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kothari</surname><given-names>RU</given-names></string-name>, <string-name name-style="western"><surname>Brott</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Broderick</surname><given-names>JP</given-names></string-name>, <etal/></person-group>. <article-title>The ABCs of measuring intracerebral hemorrhage volumes</article-title>. <source>Stroke</source>. <year>1996</year>;<volume>27</volume>(<issue>8</issue>):<fpage>1304</fpage>-<lpage>1305</lpage>. doi:<pub-id pub-id-type="doi">10.1161/01.STR.27.8.1304</pub-id><pub-id pub-id-type="pmid">8711791</pub-id></mixed-citation></ref><ref id="noi250058r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chaisinanunkul</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Adeoye</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>RJ</given-names></string-name>, <etal/>; <collab>DAWN Trial and MOST Trial Steering Committees</collab>; <collab>Additional contributors from DAWN Trial Steering Committee</collab></person-group>. <article-title>Adopting a patient-centered approach to primary outcome analysis of acute stroke trials using a utility-weighted modified Rankin scale</article-title>. <source>Stroke</source>. <year>2015</year>;<volume>46</volume>(<issue>8</issue>):<fpage>2238</fpage>-<lpage>2243</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.114.008547</pub-id><pub-id pub-id-type="pmid">26138130</pub-id><pub-id pub-id-type="pmcid">PMC4519373</pub-id></mixed-citation></ref><ref id="noi250058r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Morgan</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Dawson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Spengler</surname><given-names>D</given-names></string-name>, <etal/>; <collab>CLEAR and VISTA Investigators</collab></person-group>. <article-title>The modified Graeb score: an enhanced tool for intraventricular hemorrhage measurement and prediction of functional outcome</article-title>. <source>Stroke</source>. <year>2013</year>;<volume>44</volume>(<issue>3</issue>):<fpage>635</fpage>-<lpage>641</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.112.670653</pub-id><pub-id pub-id-type="pmid">23370203</pub-id><pub-id pub-id-type="pmcid">PMC6800016</pub-id></mixed-citation></ref><ref id="noi250058r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hanley</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Ziai</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Vahidy</surname><given-names>FS</given-names></string-name>, <etal/></person-group>. <article-title>Intracerebral hemorrhage: keep it simple</article-title>. <source>Stroke</source>. <year>2024</year>;<volume>55</volume>(<issue>12</issue>):<fpage>2942</fpage>-<lpage>2945</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.124.048533</pub-id><pub-id pub-id-type="pmid">39474689</pub-id><pub-id pub-id-type="pmcid">PMC11784926</pub-id></mixed-citation></ref><ref id="noi250058r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kellner</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Time to evacuation and functional outcome after minimally invasive endoscopic intracerebral hemorrhage evacuation</article-title>. <source>Stroke</source>. <year>2021</year>;<volume>52</volume>(<issue>9</issue>):<fpage>e536</fpage>-<lpage>e539</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.121.034392</pub-id><pub-id pub-id-type="pmid">34424739</pub-id></mixed-citation></ref><ref id="noi250058r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sondag</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schreuder</surname><given-names>FHBM</given-names></string-name>, <string-name name-style="western"><surname>Boogaarts</surname><given-names>HD</given-names></string-name>, <etal/>; <collab>Dutch ICH Surgery Trial Study Group, part of the CONTRAST consortium&#8224;</collab></person-group>. <article-title>Neurosurgical intervention for supratentorial intracerebral hemorrhage</article-title>. <source>Ann Neurol</source>. <year>2020</year>;<volume>88</volume>(<issue>2</issue>):<fpage>239</fpage>-<lpage>250</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.25732</pub-id><pub-id pub-id-type="pmid">32239722</pub-id><pub-id pub-id-type="pmcid">PMC7497162</pub-id></mixed-citation></ref><ref id="noi250058r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Polster</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Carri&#243;n-Penagos</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lyne</surname><given-names>SB</given-names></string-name>, <etal/></person-group>. <article-title>Intracerebral hemorrhage volume reduction and timing of intervention versus functional benefit and survival in the MISTIE III and STICH trials</article-title>. <source>Neurosurgery</source>. <year>2021</year>;<volume>88</volume>(<issue>5</issue>):<fpage>961</fpage>-<lpage>970</lpage>. doi:<pub-id pub-id-type="doi">10.1093/neuros/nyaa572</pub-id><pub-id pub-id-type="pmid">33475732</pub-id><pub-id pub-id-type="pmcid">PMC8190461</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-NOI250058-1"><supplementary-material id="note-NOI250058-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p>Trial Protocol</p></caption><media xlink:href="jamaneurol-e253151-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>eFigure 1. Artemis Neuro Evacuation Device (A) and Devices Used for Minimally Invasive ICH Evacuation (B)</p><p>eFigure 2. Survival Plots Showing Risk of Death Through 30 Days by Treatment Arm</p><p>eFigure 3. Survival Plots Showing Risk of Death Through 30 Days by Treatment Arm in ICH Locations</p><p>eFigure 4. Odds Ratios for the Ordinal Modified Ranking Scale Scores for MIND and ENRICH Trials</p><p>eFigure 5. Shift Analysis&#8212;Observed Modified Rankin Scale Scores at 30, 90, and 180 Days</p><p>eTable 1. Representativeness of Study Population</p><p>eTable 2. Technical and E&#64259;cacy Outcomes by ICH Location&#8212;MIS Only</p><p>eTable 3. Safety Outcomes Strati&#64257;ed by ICH Location&#8212;MIS Only</p><p>eReferences.</p></caption><media xlink:href="jamaneurol-e253151-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 3.</label><caption><p>MIND Study Investigators and Collaborators</p></caption><media xlink:href="jamaneurol-e253151-s003.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 4.</label><caption><p>Data Sharing Statement</p></caption><media xlink:href="jamaneurol-e253151-s004.pdf" position="float" orientation="portrait"/></supplementary-material></notes></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>